Literature DB >> 7579335

Synergistic effect of granulocyte colony-stimulating factor and drugs elevating extracellular adenosine on neutrophil production in mice.

M Pospíŝil1, M Hofer, V Znojil, J Vácha, J Netíková, J Holá.   

Abstract

Experimental evidence suggests that the activation of purinoceptors by extracellular adenosine can modulate proliferation and/or differentiation of hematopoietic cells. The present study was undertaken to investigate the potential interactions of this system of intercellular signaling with the effects of granulocyte colony-stimulating factor (G-CSF) on granulopoiesis in vivo. Elevation of extracellular adenosine in normal mice was induced by the joined administration of dipyridamole, a drug inhibiting the cellular uptake of adenosine, and adenosine monophosphate (AMP), an adenosine prodrug. The effects of dipyridamole, AMP, and G-CSF, administered either alone or in combinations, were evaluated. The agents were injected to mice in a 4-day regimen, and the hematologic endpoints were determined 24 hours after the completion of the treatment. It was shown that the effects of G-CSF, ie, increases in peripheral blood neutrophils, granulocyte-macrophage progenitor cells (GM-CFC), and morphologically determined granulocytic cells in femoral marrow and a decrease in the marrow erythroid cells, can be enhanced by the combination of dipyridamole plus AMP administered 30 minutes before G-CSF. Furthermore, it was ascertained that the stimulatory action of dipyridamole plus AMP was expressed particularly at lower doses of G-CSF (1.5, 3, and 4.5 micrograms/d). At higher doses of G-CSF (6 and 9 micrograms/d), the interactions were no more evident. When combining dipyridamole, AMP, and 3 micrograms of G-CSF, peripheral neutrophils increased approximately 3.9- to 4.5-fold compared with an approximate 2.2-fold increase induced by G-CSF alone. The results indicate the possible therapeutic potential of combination therapy with G-CSF and drugs increasing extracellular adenosine.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7579335

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Adenosine A2A receptors play an active role in mouse bone marrow-derived mesenchymal stem cell development.

Authors:  Majid Katebi; Mansooreh Soleimani; Bruce N Cronstein
Journal:  J Leukoc Biol       Date:  2008-12-12       Impact factor: 4.962

2.  High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBPalpha-driven myeloid differentiation.

Authors:  Ji Suk Chang; Ramasamy Santhanam; Rossana Trotta; Paolo Neviani; Anna M Eiring; Edward Briercheck; Mattia Ronchetti; Denis C Roy; Bruno Calabretta; Michael A Caligiuri; Danilo Perrotti
Journal:  Blood       Date:  2007-05-02       Impact factor: 22.113

3.  The pharmacological activation of adenosine A1 and A 3 receptors does not modulate the long- or short-term repopulating ability of hematopoietic stem and multipotent progenitor cells in mice.

Authors:  Michal Hofer; Milan Pospíšil; Zuzana Hoferová; Denisa Komůrková; Petr Páral; Filipp Savvulidi; Luděk Sefc
Journal:  Purinergic Signal       Date:  2012-12-15       Impact factor: 3.765

Review 4.  Purinergic signalling and immune cells.

Authors:  Geoffrey Burnstock; Jean-Marie Boeynaems
Journal:  Purinergic Signal       Date:  2014-10-29       Impact factor: 3.765

5.  A₃ adenosine receptor allosteric modulator induces an anti-inflammatory effect: in vivo studies and molecular mechanism of action.

Authors:  Shira Cohen; Faina Barer; Sara Bar-Yehuda; Adriaan P IJzerman; Kenneth A Jacobson; Pnina Fishman
Journal:  Mediators Inflamm       Date:  2014-10-13       Impact factor: 4.711

Review 6.  Combining Pharmacological Countermeasures to Attenuate the Acute Radiation Syndrome-A Concise Review.

Authors:  Michal Hofer; Zuzana Hoferová; Daniel Depeš; Martin Falk
Journal:  Molecules       Date:  2017-05-19       Impact factor: 4.411

Review 7.  The role of adenosine receptor agonists in regulation of hematopoiesis.

Authors:  Michal Hofer; Milan Pospisil; Lenka Weiterova; Zuzana Hoferova
Journal:  Molecules       Date:  2011-01-17       Impact factor: 4.411

8.  Inhibition of primary colon carcinoma growth and liver metastasis by the A3 adenosine receptor agonist CF101.

Authors:  G Ohana; S Bar-Yehuda; A Arich; L Madi; Z Dreznick; L Rath-Wolfson; D Silberman; G Slosman; P Fishman
Journal:  Br J Cancer       Date:  2003-10-20       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.